Marshall Edwards in $2 million private placement

Marshall Edwards (NASDAQ:MSHL) has entered into a definitive agreement with its majority shareholder, Novogen Ltd., to sell common stock in a private placement for gross proceeds of $2 million, before deducting fees and expenses of the offering, through the sale of approximately 1.33 million common shares. “This transaction is another indication of Novogen’s ongoing support [...]

Marshall Edwards taking Big Pharma clinical path

Marshall Edwards (NASDAQ:MSHL), with one cancer drug now undergoing clinical testing and another set for early 2012, is planning to take a road less traveled by early-stage oncology companies and one that’s more in tune with Big Pharma. “As soon as we’ve established a safe dose with our ME-143 and ME-344 compounds, we’re going to [...]

Bringing sunshine to cancer patients

After many pharma and biotech disappointments using vitamin D in oncology, Receptor Therapeutics may be on the precipice of bringing sunshine to cancer patients. All it needs is the money to begin clinical development. “Many experts contend that about half the human population is deficient in vitamin D,” CEO Dr. Joseph Elliot says in an [...]

DiagnoCure names president for U.S. lab unit

DiagnoCure Inc. (TSX:CUR) has appointed Valerie Palmieri as president of DiagnoCure Oncology Laboratories, its U.S. subsidiary. Ms. Palmieri brings more than 25 years experience in the laboratory industry to DiagnoCure, including several executive positions at DIANON Systems and Laboratory Corp. of America.  For the past year, Ms. Palmieri was a consultant with Momentum Consulting, which [...]

DiagnoCure’s PCA3 gets boost from GSK study

Two major studies presented last week at the Genitourinary symposium of the American Society of Clinical Oncology in San Francisco featured DiagnoCure’s PCA3 molecular test on subsets of patients in GlaxoSmithKline’s REDUCE trial of its prostate cancer drug dutasteride. “This four-year, multicentre, worldwide study is the largest to date performed on DiagnoCure’s PCA3 marker,” DiagnoCure (TSX:CUR) [...]